Erasca, Inc.
A clinical-stage biopharmaceutical company developing medicines for cancers driven by the RAS/MAPK pathway, one of the most frequently mutated signaling routes in human tumors. Founded in San Diego in 2018, its name blends "RAS" with "era," reflecting a mission to open a new era in treating RAS-driven cancers. The company is building a pipeline of experimental drugs aimed at this stubborn family of cancer-causing proteins.
Bought 2.20M
Bought 1.26M
Bought 200.0K · Sold 200.0K
Bought 150.0K
Bought 20.0K
Bought 6.2K
Granted 203.9K · Bought 900 · Sold 200.0K
Bought 22.0K
Granted 20.0K · Sold 20.0K
Bought 6.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lim Jonathan EChairman & CEO, Director, 10% owner · 7 transactions | — | 44.25Mas of Dec 2023 | — | 2.20M | — |
| Lim Conyee T. +2 co-filers10% owner, See Remarks, Director, 10% owner · 2 transactions | — | 32.06Mas of Jul 2021 | — | — | — |
| Chen Bihua +3 co-filersDirector · 3 transactions | — | 21.63Mas of Jun 2023 | — | 1.26M | — |
| Chen BihuaDirector · 2 transactions | — | 20.81Mas of Jun 2022 | — | 200.0K | 200.0K |
| Burow Kristina +8 co-filers10% owner · 2 transactions | — | 11.06Mas of Jul 2021 | — | — | — |
| Casdin Alexander W.Director · 7 transactions | — | 667.7Kas of May 2024 | — | 150.0K | — |
| Wei LinChief Medical Officer · 3 transactions | — | 315.8Kas of Feb 2023 | — | — | — |
| Chacko David M.CFO and CBO · 7 transactions | — | 280.0K | — | — | — |
| Bristol James ArthurDirector · 1 transaction | — | 207.5Kas of Dec 2022 | — | 20.0K | — |
| Multani Pratik SDirector · 3 transactions | — | 172.9Kas of May 2025 | — | 6.2K | — |
| Garner EbunChief Legal Officer · 12 transactions | — | 105.1K | 203.9K | 900 | 200.0K |
| Start Valerie Denise HardingDirector · 3 transactions | — | 22.0Kas of Dec 2023 | — | 22.0K | — |
| Morris ShannonChief Medical Officer · 2 transactions | — | 20.0K | 20.0K | — | 20.0K |
| Hambleton JulieDirector · 1 transaction | — | 6.0Kas of Jul 2021 | — | 6.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +3.44M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.